Article(id=1327673209094254753, tenantId=1146029695717560320, journalId=1319690259887390882, issueId=1327673173845324667, articleNumber=null, orderNo=null, doi=10.16522/j.cnki.cjph.2022.04.005, pmid=null, cstr=null, oa=null, hot=null, price=null, onlineType=0, articleFormat=0, articleType=null, articleTypeStr=null, receivedDate=1631808000000, receivedDateStr=2021-09-17, revisedDate=null, revisedDateStr=null, acceptedDate=null, acceptedDateStr=null, onlineDate=1794471560022, onlineDateStr=2026-11-12, pubDate=1649520000000, pubDateStr=2022-04-10, doiRegisterDate=null, doiRegisterDateStr=null, onlineIssueDate=1794471560022, onlineIssueDateStr=2026-11-12, onlineJustAcceptDate=null, onlineJustAcceptDateStr=null, onlineFirstDate=null, onlineFirstDateStr=null, sourceXml=null, magXml=null, createTime=1794471560022, creator=13701087609, updateTime=1794471560022, updator=13701087609, issue=Issue{id=1327673173845324667, tenantId=1146029695717560320, journalId=1319690259887390882, year='2022', volume='53', issue='4', pageStart='425', pageEnd='590', issueExtLink='null', onlineDate='null', pubDate='1649520000000', pubDateStr='2022-04-10', beforeIssueId=null, nextIssueId=null, price=null, status=1, issueComplete=1, articleOrder=1, issueType=-1, specialIssue=null, createTime=1794471551619, creator='13701087609', updateTime=1794472266725, updator='13701087609', preIssue=null, nextIssue=null, articleTotal=null, ext={EN=IssueExt(id=1327676173842231314, tenantId=1146029695717560320, journalId=1319690259887390882, issueId=1327673173845324667, language=EN, specialIssueTitle=, coverIllustrator=null, specialIssueEditor=, specialIssueAbout=), CN=IssueExt(id=1327676173842231315, tenantId=1146029695717560320, journalId=1319690259887390882, issueId=1327673173845324667, language=CN, specialIssueTitle=, coverIllustrator=null, specialIssueEditor=, specialIssueAbout=)}, issueFiles=null, downloadFileDto=null}, startPage=464, endPage=473, ext={EN=ArticleExt(id=1327673209333330082, articleId=1327673209094254753, tenantId=1146029695717560320, journalId=1319690259887390882, language=EN, title=Small Molecule Cyclin-dependent Kinase 4/6 Inhibitor Drugs and Their Patent Research, columnId=1327671134809600231, journalTitle=Chinese Journal of Pharmaceuticals, columnName=Review, runingTitle=null, highlight=null, articleAbstract=

In this study, five small-molecule cyclin-dependent kinase 4/6(CDK4/6) inhibitors, marketed at home and abroad, are analyzed and researched in detail, so does their patent information. To provide practical patent information and references for Chinese pharmaceutical companies to establish and develop projects of CDK4/6 inhibitors for innovative or generic drugs, as well as new patent mining, patent protection and layout, this study mainly focuses on the patents of product, crystalline form, salt form, process, formulation, drug combination, new use and development derivatives.

, authors=Fan GE1, Jian SUN2, Lu HUANG3, 4, *, authorsList=Fan GE, Jian SUN, Lu HUANG, authorCompany=null, correspAuthors=Lu HUANG, authorNote=null, correspAuthorsNote=null, copyrightStatement=null, copyrightOwner=null, extLink=null, articleAbsUrl=null, sourceXml=null, magXml=null, pdfUrl=null, pdf=null, pdfFileSize=null, pdfExtLink=null, richHtmlUrl=null, mobilePdfUrl=null, reviewReport=null, pdfFirstPage=null, abstractGraph=null, abstractGraphContent=null, abstractVideo=null, citation=null, cebUrl=null, magXmlContent=null, mapNumber=null, fund=null), CN=ArticleExt(id=1327673210063138979, articleId=1327673209094254753, tenantId=1146029695717560320, journalId=1319690259887390882, language=CN, title=小分子周期蛋白依赖性激酶4/6抑制剂药物及其专利研究, columnId=1327671135019315436, journalTitle=中国医药工业杂志, columnName=综述, runingTitle=null, highlight=null, articleAbstract=

本研究重点对国内外已上市的5个小分子周期蛋白依赖性激酶4/6(CDK4/6)抑制剂药物及其专利信息进行解读,详细分析和研究了各药物在不同技术主题如化合物、晶型、盐型、制备工艺、药物制剂、药物组合物和(或)联合给药、药物新用途、衍生物等方面的专利情况,以期为我国医药企业进行CDK4/6抑制剂的创新药或仿制药产品立项与开发,以及进行新的专利挖掘、专利保护与布局时,提供有效的专利信息和文献依据。

, authors=葛凡1, 孙建2, 黄璐3, 4, *, authorsList=葛凡, 孙建, 黄璐, authorCompany=null, correspAuthors=黄璐, authorNote=

葛凡(1980—),男,博士,专利代理师,诉讼代理人,从事医药知识产权工作。

, correspAuthorsNote=
黄璐(1982—),男,高级工程师,从事新药开发与医药知识产权研究。E-mail:
, copyrightStatement=null, copyrightOwner=null, extLink=null, articleAbsUrl=null, sourceXml=AsVJrVsF+qlM7Dj3u7XTOA==, magXml=EuUX967XzAVGx/pHc45rNg==, pdfUrl=null, pdf=+VfBFpy9i+GkNboO/lAc7w==, pdfFileSize=1662716, pdfExtLink=null, richHtmlUrl=null, mobilePdfUrl=null, reviewReport=null, pdfFirstPage=null, abstractGraph=null, abstractGraphContent=null, abstractVideo=null, citation=null, cebUrl=null, magXmlContent=CsjVKSfN3alN0UBYLrOmYQ==, mapNumber=null, fund=null)}, authors=[Author(id=1327673211837329586, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327673209094254753, orderNo=0, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1327673211946381492, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327673209094254753, authorId=1327673211837329586, language=EN, stringName=Fan GE, firstName=Fan, middleName=null, lastName=GE, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, address=1.FIWIS Intellectual Property Law Firm, Beijing 100032, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1327673212009296053, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327673209094254753, authorId=1327673211837329586, language=CN, stringName=葛凡, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, address=1.北京孚睿湾知识产权代理事务所,北京 100032, bio={"content":"

葛凡(1980—),男,博士,专利代理师,诉讼代理人,从事医药知识产权工作。

"}, bioImg=null, bioContent=

葛凡(1980—),男,博士,专利代理师,诉讼代理人,从事医药知识产权工作。

, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1327673211464036516, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327673209094254753, xref=1., ext=[AuthorCompanyExt(id=1327673211472425125, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327673209094254753, companyId=1327673211464036516, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.FIWIS Intellectual Property Law Firm, Beijing 100032), AuthorCompanyExt(id=1327673211480813734, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327673209094254753, companyId=1327673211464036516, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.北京孚睿湾知识产权代理事务所,北京 100032)])]), Author(id=1327673212076404919, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327673209094254753, orderNo=1, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1327673212156096697, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327673209094254753, authorId=1327673212076404919, language=EN, stringName=Jian SUN, firstName=Jian, middleName=null, lastName=SUN, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=2, address=2.Kanazawa Institute of Technology, Tokyo, Japan 105-0002, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1327673212290314426, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327673209094254753, authorId=1327673212076404919, language=CN, stringName=孙建, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=2, address=2.金泽工业大学,日本 东京都 105-0002, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1327673211556311207, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327673209094254753, xref=2., ext=[AuthorCompanyExt(id=1327673211564699816, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327673209094254753, companyId=1327673211556311207, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.Kanazawa Institute of Technology, Tokyo, Japan 105-0002), AuthorCompanyExt(id=1327673211568894121, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327673209094254753, companyId=1327673211556311207, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.金泽工业大学,日本 东京都 105-0002)])]), Author(id=1327673212403560636, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327673209094254753, orderNo=2, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=47153437@qq.com, emailSecond=null, emailThird=null, correspondingAuthor=1, authorType=1, ext={EN=AuthorExt(id=1327673212525195455, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327673209094254753, authorId=1327673212403560636, language=EN, stringName=Lu HUANG, firstName=Lu, middleName=null, lastName=HUANG, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=3, 4, *, address=3.School of Chemical Engineering and Pharmacy, Wuhan Institute of Technology, Wuhan 430205
4.School of Pharmacutical Sciences, Wuhan University, Wuhan 430071, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1327673212617470144, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327673209094254753, authorId=1327673212403560636, language=CN, stringName=黄璐, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=3, 4, *, address=3.武汉工程大学化工与制药学院,湖北 武汉 430205
4.武汉大学药学院,湖北 武汉 430071, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1327673211627614378, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327673209094254753, xref=3., ext=[AuthorCompanyExt(id=1327673211656974507, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327673209094254753, companyId=1327673211627614378, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=3.School of Chemical Engineering and Pharmacy, Wuhan Institute of Technology, Wuhan 430205), AuthorCompanyExt(id=1327673211673751724, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327673209094254753, companyId=1327673211627614378, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=3.武汉工程大学化工与制药学院,湖北 武汉 430205)]), AuthorCompany(id=1327673211753443502, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327673209094254753, xref=4., ext=[AuthorCompanyExt(id=1327673211766026415, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327673209094254753, companyId=1327673211753443502, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=4.School of Pharmacutical Sciences, Wuhan University, Wuhan 430071), AuthorCompanyExt(id=1327673211774415024, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327673209094254753, companyId=1327673211753443502, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=4.武汉大学药学院,湖北 武汉 430071)])])], keywords=[Keyword(id=1327673212726522050, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327673209094254753, language=EN, orderNo=1, keyword=CDK4/6 inhibitor), Keyword(id=1327673212785242307, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327673209094254753, language=EN, orderNo=2, keyword=palbociclib), Keyword(id=1327673212873322692, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327673209094254753, language=EN, orderNo=3, keyword=ribociclib), Keyword(id=1327673212936237253, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327673209094254753, language=EN, orderNo=4, keyword=abemaciclib), Keyword(id=1327673212990763206, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327673209094254753, language=EN, orderNo=5, keyword=trilaciclib), Keyword(id=1327673213049483463, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327673209094254753, language=EN, orderNo=6, keyword=dalpiciclib), Keyword(id=1327673213116592328, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327673209094254753, language=EN, orderNo=7, keyword=patent research), Keyword(id=1327673213175312585, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327673209094254753, language=CN, orderNo=1, keyword=CDK4/6抑制剂), Keyword(id=1327673213234032842, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327673209094254753, language=CN, orderNo=2, keyword=哌柏西利), Keyword(id=1327673213284364491, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327673209094254753, language=CN, orderNo=3, keyword=利柏西利), Keyword(id=1327673213359861964, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327673209094254753, language=CN, orderNo=4, keyword=阿贝西利), Keyword(id=1327673213418582221, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327673209094254753, language=CN, orderNo=5, keyword=曲拉西利), Keyword(id=1327673213489885390, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327673209094254753, language=CN, orderNo=6, keyword=达尔西利), Keyword(id=1327673213565382863, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327673209094254753, language=CN, orderNo=7, keyword=专利研究)], refs=[Reference(id=1327673213741543633, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327673209094254753, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[1], rfOrder=0, authorNames=null, journalName=null, refType=null, unstructuredReference=TOOGOOD P L, HARVEY P J, REPINE J T, et al.Discovery of a potent and selective inhibitor of cyclin-dependent kinase 4/6 [J].J Med Chem, 2005, 48(7): 2388-2406., articleTitle=null, refAbstract=null), Reference(id=1327673213825429715, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327673209094254753, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[2], rfOrder=1, authorNames=null, journalName=null, refType=null, unstructuredReference=VANDERWEL S N, HARVEY P J, MCNAMARA D J, et al.Pyrido[2,3-d]pyrimidin-7-ones as specific inhibitors of cyclin-dependent kinase 4 [J].J Med Chem, 2005, 48(7):2371-2387., articleTitle=null, refAbstract=null), Reference(id=1327673213905121492, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327673209094254753, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[3], rfOrder=2, authorNames=null, journalName=null, refType=null, unstructuredReference=PARDEE A B.G1 events and regulation of cell proliferation[J].Science, 1989, 246(4930): 603-608., articleTitle=null, refAbstract=null), Reference(id=1327673213963841749, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327673209094254753, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[4], rfOrder=3, authorNames=null, journalName=null, refType=null, unstructuredReference=FINN R S, DERING J, CONKLIN D, et al.PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro [J].Breast Cancer Res,2009, 11(5): R77., articleTitle=null, refAbstract=null), Reference(id=1327673214022562006, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327673209094254753, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[5], rfOrder=4, authorNames=null, journalName=null, refType=null, unstructuredReference=VANARSDALE T, BOSHOFF C, ARNDT K T, et al.Molecular pathways: targeting the cyclin D-CDK4/6 axis for cancer treatment [J].Clin Cancer Res, 2015, 21(13): 2905-2910., articleTitle=null, refAbstract=null), Reference(id=1327673215771586775, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327673209094254753, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[6], rfOrder=5, authorNames=null, journalName=null, refType=null, unstructuredReference=ASGHAR U, WITKIEWICZ A K, TURNER N C, et al.The history and future of targeting cyclin-dependent kinases in cancer therapy [J].Nat Rev Drug Discov, 2015, 14(2):130-146., articleTitle=null, refAbstract=null), Reference(id=1327673215863861464, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327673209094254753, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[7], rfOrder=6, authorNames=null, journalName=null, refType=null, unstructuredReference=KLEIN M E, KOVATCHEVA M, DAVIS L E, et al.CDK4/6 inhibitors: the mechanism of action may not be as simple as once thought [J].Cancer Cell, 2018, 34(1):9-20., articleTitle=null, refAbstract=null), Reference(id=1327673215922581721, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327673209094254753, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[8], rfOrder=7, authorNames=null, journalName=null, refType=null, unstructuredReference=Clarivate Analytics公司.Cortellis数据库[EB/OL].[2021-11-23].https://www.cortellis.com/intelligence., articleTitle=null, refAbstract=null), Reference(id=1327673215989690586, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327673209094254753, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[9], rfOrder=8, authorNames=null, journalName=null, refType=null, unstructuredReference=DHILLON S.Palbociclib: first global approval [J].Drugs,2015, 75(5): 543-551., articleTitle=null, refAbstract=null), Reference(id=1327673216056799451, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327673209094254753, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[10], rfOrder=9, authorNames=null, journalName=null, refType=null, unstructuredReference=LU J.Palbociclib: a first-in-class CDK4/CDK6 inhibitor for the treatment of hormone-receptor positive advanced breast cancer [J].J Hematol Oncol, 2015, 8(1): 98., articleTitle=null, refAbstract=null), Reference(id=1327673216136491228, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327673209094254753, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[11], rfOrder=10, authorNames=null, journalName=null, refType=null, unstructuredReference=U.S.FDA.Drugs@FDA: FDA-approved drugs-Ibrance(palbociclib) NDA #207103 [EB/OL].[2021-08-12].https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=207103., articleTitle=null, refAbstract=null), Reference(id=1327673216203600093, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327673209094254753, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[12], rfOrder=11, authorNames=null, journalName=null, refType=null, unstructuredReference=U.S.FDA.Palbociclib(Ibrance)[EB/OL].[2021-08-12].https://www.fda.gov/drugs/resources-information-approved-drugs/palbociclib-ibrance., articleTitle=null, refAbstract=null), Reference(id=1327673216287486174, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327673209094254753, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[13], rfOrder=12, authorNames=null, journalName=null, refType=null, unstructuredReference=U.S.FDA.Drugs@FDA: FDA-approved drugs-Ibrance(palbociclib) NDA #212436 [EB/OL].[2021-08-12].https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=212436., articleTitle=null, refAbstract=null), Reference(id=1327673216346206431, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327673209094254753, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[14], rfOrder=13, authorNames=null, journalName=null, refType=null, unstructuredReference=U.S.FDA.Ribociclib (Kisqali)[EB/OL].[2021-08-12].https://www.fda.gov/drugs/resources-information-approved-drugs/ribociclib-kisqali., articleTitle=null, refAbstract=null), Reference(id=1327673216417509600, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327673209094254753, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[15], rfOrder=14, authorNames=null, journalName=null, refType=null, unstructuredReference=BRAAL C L, JONGBLOED E M, WILTING S M, et al.Inhibiting CDK4/6 in breast cancer with palbociclib, ribociclib, and abemaciclib: similarities and differences [J].Drugs, 2021, 81(3): 317-331., articleTitle=null, refAbstract=null), Reference(id=1327673216484618465, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327673209094254753, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[16], rfOrder=15, authorNames=null, journalName=null, refType=null, unstructuredReference=KNUDSEN E S, WITKIEWICZ A K.Defining the transcriptional and biological response to CDK4/6 inhibition in relation to ER+/HER2- breast cancer [J].Oncotarget,2016, 7(43): 69111-69123., articleTitle=null, refAbstract=null), Reference(id=1327673216551727330, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327673209094254753, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[17], rfOrder=16, authorNames=null, journalName=null, refType=null, unstructuredReference=U.S.FDA.FDA approves abemaciclib for HR-positive, HER2-negative breast cancer [EB/OL].[2021-08-12].https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-abemaciclib-hr-positive-her2-negative-breast-cancer., articleTitle=null, refAbstract=null), Reference(id=1327673216623030499, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327673209094254753, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[18], rfOrder=17, authorNames=null, journalName=null, refType=null, unstructuredReference=SLEDGE G W Jr, TOI M, NEVEN P, et al.MONARCH 2: abemaciclib in combination with fulvestrant in women with HR+/HER2 advanced breast cancer who had progressed while receiving endocrine therapy [J].J Clin Oncol, 2017,35(25): 2875-2884., articleTitle=null, refAbstract=null), Reference(id=1327673216732082404, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327673209094254753, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[19], rfOrder=18, authorNames=null, journalName=null, refType=null, unstructuredReference=GOETZ M P, TOI M, CAMPONE M, et al.MONARCH 3: abemaciclib as initial therapy for advanced breast cancer[J].J Clin Oncol, 2017, 35(32): 3638-3646., articleTitle=null, refAbstract=null), Reference(id=1327673216807579877, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327673209094254753, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[20], rfOrder=19, authorNames=null, journalName=null, refType=null, unstructuredReference=U.S.FDA.FDA approves abemaciclib as initial therapy for HR-positive, HER2-negative metastatic breast cancer[EB/OL].[2021-08-12].https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-abemaciclib-initial-therapy-hr-positive-her2-negative-metastatic-breast-cancer., articleTitle=null, refAbstract=null), Reference(id=1327673216870494438, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327673209094254753, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[21], rfOrder=20, authorNames=null, journalName=null, refType=null, unstructuredReference=李瑞鹏,夏广新,赵建宏,等.阿贝西利的合成研究进展[J].中国医药工业杂志,2021,52(9):1142-1153., articleTitle=null, refAbstract=null), Reference(id=1327673216945991911, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327673209094254753, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[22], rfOrder=21, authorNames=null, journalName=null, refType=null, unstructuredReference=PARYLO S, VENNEPUREDDY A, DHAR V, et al.Role of cyclin-dependent kinase 4/6 inhibitors in the current and future eras of cancer treatment [J].J Oncol Pharm Pract,2019, 25(1): 110-129., articleTitle=null, refAbstract=null), Reference(id=1327673217021489384, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327673209094254753, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[23], rfOrder=22, authorNames=null, journalName=null, refType=null, unstructuredReference=U.S.FDA.FDA approves drug to reduce bone marrow suppression caused by chemotherapy [EB/OL].[2021-08-12].https://www.fda.gov/news-events/press-announcements/fda-approves-drug-reduce-bone-marrow-suppression-caused-chemotherapy., articleTitle=null, refAbstract=null), Reference(id=1327673217122152681, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327673209094254753, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[24], rfOrder=23, authorNames=null, journalName=null, refType=null, unstructuredReference=先声药业官网.先声药业和G1 Therapeutics宣布签署有关Trilaciclib产品在大中华地区的独家许可协议[EB/OL].[2021-08-12].https://www.simcere.com/news/detail.aspx?mtt=98., articleTitle=null, refAbstract=null), Reference(id=1327673217193455850, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327673209094254753, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[25], rfOrder=24, authorNames=null, journalName=null, refType=null, unstructuredReference=U.S.FDA.Drugs@FDA: FDA-Approved Drugs, labels for NDA 214200 [EB/OL].[2021-08-12].https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214200s000lbl.pdf., articleTitle=null, refAbstract=null), Reference(id=1327673217268953323, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327673209094254753, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[26], rfOrder=25, authorNames=null, journalName=null, refType=null, unstructuredReference=XU B, ZHANG Q, ZHANG P, et al.Dalpiciclib versus placebo plus fulvestrant in HR+/HER2- advanced breast cancer that relapsed or progressed on previous endocrine therapy (DAWNA-1): amulticenter, randomized, phase 3 study [J].J Clin Oncol, 2021, 39(15_suppl): 1002., articleTitle=null, refAbstract=null), Reference(id=1327673217357033708, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327673209094254753, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[27], rfOrder=26, authorNames=null, journalName=null, refType=null, unstructuredReference=黄璐,王亚楠,陈进,等.新丝裂原激活蛋白激酶激酶1/2抑制剂:司美替尼[J].中国新药与临床杂志,2021,40(8):562-568., articleTitle=null, refAbstract=null), Reference(id=1327673217453502701, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327673209094254753, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[28], rfOrder=27, authorNames=null, journalName=null, refType=null, unstructuredReference=黄璐,古双喜,洪怡.选择性转染重排酪氨酸激酶抑制剂概述及其专利研究[J].中国医药工业杂志,2021,52(10):1291-1296., articleTitle=null, refAbstract=null), Reference(id=1327673217516417262, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327673209094254753, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[29], rfOrder=28, authorNames=null, journalName=null, refType=null, unstructuredReference=黄璐,余浩,张长春,等.药品研发过程中的知识产权制度及运用[J].中国新药杂志,2019,28(1):10-16., articleTitle=null, refAbstract=null)], funds=[Fund(id=1327673213640880336, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327673209094254753, awardId=18BFX168, language=CN, fundingSource=国家社会科学基金项目(18BFX168), fundOrder=null, country=null)], companyList=[AuthorCompany(id=1327673211464036516, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327673209094254753, xref=1., ext=[AuthorCompanyExt(id=1327673211472425125, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327673209094254753, companyId=1327673211464036516, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.FIWIS Intellectual Property Law Firm, Beijing 100032), AuthorCompanyExt(id=1327673211480813734, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327673209094254753, companyId=1327673211464036516, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.北京孚睿湾知识产权代理事务所,北京 100032)]), AuthorCompany(id=1327673211556311207, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327673209094254753, xref=2., ext=[AuthorCompanyExt(id=1327673211564699816, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327673209094254753, companyId=1327673211556311207, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.Kanazawa Institute of Technology, Tokyo, Japan 105-0002), AuthorCompanyExt(id=1327673211568894121, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327673209094254753, companyId=1327673211556311207, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.金泽工业大学,日本 东京都 105-0002)]), AuthorCompany(id=1327673211627614378, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327673209094254753, xref=3., ext=[AuthorCompanyExt(id=1327673211656974507, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327673209094254753, companyId=1327673211627614378, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=3.School of Chemical Engineering and Pharmacy, Wuhan Institute of Technology, Wuhan 430205), AuthorCompanyExt(id=1327673211673751724, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327673209094254753, companyId=1327673211627614378, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=3.武汉工程大学化工与制药学院,湖北 武汉 430205)]), AuthorCompany(id=1327673211753443502, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327673209094254753, xref=4., ext=[AuthorCompanyExt(id=1327673211766026415, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327673209094254753, companyId=1327673211753443502, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=4.School of Pharmacutical Sciences, Wuhan University, Wuhan 430071), AuthorCompanyExt(id=1327673211774415024, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327673209094254753, companyId=1327673211753443502, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=4.武汉大学药学院,湖北 武汉 430071)])], figs=null, attaches=null, journal=Journal(id=1319689822849302687, delFlag=0, nameCn=中国医药工业杂志, nameEn=Chinese Journal of Pharmaceuticals, nameHistory1=null, nameHistory2=null, issn=1001-8255, eissn=null, cn=31-1243/R, coden=ZYGZEA, periodic=0, language=CN, oaType=null, ccby=null, superviseOffice=null, ownerOffice=null, pubOffice=null, editorOffice=null, officeType=null, aims=null, clcCode=null, officeProv=null, officeCity=null, officeAddr=null, officeZip=null, officeEmail=null, officePhone=null, editDirector=null, officeDirector=null, officeDirectorPhone=null, officeStaffNum=null, officeEmpNum=null, coverPicUrl=etiWDuwx2KO274LHw88KJA==, journalPrice=null, startedYear=null, abbrevIsoEn=Chinese Journal of Pharmaceuticals, journalRemark=null, publicationField=null, createdTime=1792568172420, updatedTime=1792747450744, createdBy=18614031015, updatedBy=13701087609, firstLetterCn=Z, firstLetterEn=Z, subjectCode=Medical and Pharmaceutical Sciences, subjectName=null, subjectCodeEn=Medical and Pharmaceutical Sciences, subjectNameEn=null, picCn=etiWDuwx2KO274LHw88KJA==, picEn=ip9NF4dK57AmNrCiZ6hmdw==, jcr=null, cjcr=null, exts=[JournalExt(id=1320441770761105589, language=CN, name=中国医药工业杂志, nameHistory1=null, nameHistory2=null, managedBy=, sponsoredBy=, publishedBy=, editorOffice=, officeProv=null, officeCity=null, officeAddr=, officeZip=, editDirector=, officeDirector=null, officePhone=null, coverPicUrl=null, journalRemark=, submitArticleUrl=null, websiteUrl=, createdTime=1792747450771, updatedTime=1792747450771, createdBy=13701087609, updatedBy=13701087609, submissionGuidelinesUrl=, submissionAuthorUrl=https://zgyygyauthor.cast.org.cn/webm, submissionEditorUrl=https://zgyygyeditor.cast.org.cn/webm, submissionReviewUrl=https://zgyygyauthor.cast.org.cn/webm, submissionCeEditorUrl=https://zgyygyeditor.cast.org.cn/webm, submissionAeEditorUrl=https://zgyygyeditor.cast.org.cn/webm, option={"copyright":""}), JournalExt(id=1320441770819825846, language=EN, name=Chinese Journal of Pharmaceuticals, nameHistory1=null, nameHistory2=null, managedBy=, sponsoredBy=, publishedBy=, editorOffice=, officeProv=null, officeCity=null, officeAddr=, officeZip=, editDirector=, officeDirector=null, officePhone=null, coverPicUrl=null, journalRemark=, submitArticleUrl=null, websiteUrl=, createdTime=1792747450785, updatedTime=1792747450785, createdBy=13701087609, updatedBy=13701087609, submissionGuidelinesUrl=, submissionAuthorUrl=https://zgyygyauthor.cast.org.cn/webm, submissionEditorUrl=https://zgyygyeditor.cast.org.cn/webm, submissionReviewUrl=https://zgyygyauthor.cast.org.cn/webm, submissionCeEditorUrl=https://zgyygyeditor.cast.org.cn/webm, submissionAeEditorUrl=https://zgyygyeditor.cast.org.cn/webm, option={"copyright":""})], databaseList=null, tenantJournalId=1319690259887390882, websiteList=[Website(id=1319720771623174732, webName=null, webTitle=null, webDomain=null, webCopyrigh=null, webIpcNo=null, seoTitle=null, seoKeywords=null, seoDescription=null, tenantJournalId=null, journalId=1319690259887390882, journalNameCn=null, journalNameEn=null, grayFlag=null, tenantId=1146029695717560320, platformId=null, journalGroupId=null, journalGroupNameCn=null, journalGroupNameEn=null, type=1, domain=https://castjournals.cast.org.cn/joweb/zgyygy/CN, language=CN, createTime=1792575551181, createBy=18614031015, updateTime=1792746040843, updateBy=18614031015, name=中国医药工业杂志-中文, tplId=1146099689490845704, title=中国医药工业杂志, delFlag=0, indexPage=/home, props=[WebsiteProps(id=1321428487504769041, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771623174732, code=articleTextType, value=kx, createTime=1792982702375, updateTime=1792982702375, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428487475408910, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771623174732, code=banner, value=https://castjournals.cast.org.cn/joweb/zgyygy/CN/file/pic?fileId=i/3+mr8MqWvs6ArWn9VK7w==, createTime=1792982702368, updateTime=1792982702368, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428487538323476, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771623174732, code=grayFlag, value=0, createTime=1792982702383, updateTime=1792982702383, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428487462825997, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771623174732, code=logo, value=https://castjournals.cast.org.cn/joweb/zgyygy/CN/file/pic?fileId=7mfvc3zMp/tsQUIOlJrNFQ==, createTime=1792982702365, updateTime=1792982702365, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428487571877910, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771623174732, code=minRunFlag, value=0, createTime=1792982702391, updateTime=1792982702391, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428487496380432, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771623174732, code=picServerUrl, value=https://castjournals.cast.org.cn/joweb/zgyygy/CN/file/pic, createTime=1792982702373, updateTime=1792982702373, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428487563489301, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771623174732, code=silenceFlag, value=0, createTime=1792982702389, updateTime=1792982702389, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428487483797519, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771623174732, code=staticResourcePath, value=https://castjournals.cast.org.cn/joweb/cast_kjdb_cn_619/, createTime=1792982702370, updateTime=1792982702370, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428487517351954, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771623174732, code=themeColor, value=null, createTime=1792982702378, updateTime=1792982702378, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428487525740563, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771623174732, code=themeStyle, value=.style-1 .main-menu ul>li { margin-right: 18px; } @media (max-width: 1442px) { .style-1 .main-menu ul>li a { font-size: 16px; padding: 10px 0; } }, createTime=1792982702380, updateTime=1792982702380, creator=18614031015, updator=18614031015)]), Website(id=1319720771702866512, webName=null, webTitle=null, webDomain=null, webCopyrigh=null, webIpcNo=null, seoTitle=null, seoKeywords=null, seoDescription=null, tenantJournalId=null, journalId=1319690259887390882, journalNameCn=null, journalNameEn=null, grayFlag=null, tenantId=1146029695717560320, platformId=null, journalGroupId=null, journalGroupNameCn=null, journalGroupNameEn=null, type=1, domain=https://castjournals.cast.org.cn/joweb/zgyygy/EN, language=EN, createTime=1792575551200, createBy=18614031015, updateTime=1792746037543, updateBy=18614031015, name=中国医药工业杂志-英文, tplId=1146101810881728533, title=Chinese Journal of Pharmaceuticals, delFlag=0, indexPage=/home, props=[WebsiteProps(id=1321428509638111261, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771702866512, code=articleTextType, value=kx, createTime=1792982707652, updateTime=1792982707652, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428509579391002, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771702866512, code=banner, value=https://castjournals.cast.org.cn/joweb/zgyygy/EN/file/pic?fileId=i/3+mr8MqWvs6ArWn9VK7w==, createTime=1792982707638, updateTime=1792982707638, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428509680054304, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771702866512, code=grayFlag, value=0, createTime=1792982707662, updateTime=1792982707662, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428509566808089, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771702866512, code=logo, value=https://castjournals.cast.org.cn/joweb/zgyygy/EN/file/pic?fileId=7mfvc3zMp/tsQUIOlJrNFQ==, createTime=1792982707635, updateTime=1792982707635, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428509701025826, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771702866512, code=minRunFlag, value=0, createTime=1792982707667, updateTime=1792982707667, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428509629722652, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771702866512, code=picServerUrl, value=https://castjournals.cast.org.cn/joweb/zgyygy/EN/file/pic, createTime=1792982707650, updateTime=1792982707650, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428509688442913, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771702866512, code=silenceFlag, value=0, createTime=1792982707664, updateTime=1792982707664, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428509587779611, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771702866512, code=staticResourcePath, value=https://castjournals.cast.org.cn/joweb/cast_kjdb_en_623/, createTime=1792982707640, updateTime=1792982707640, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428509663277086, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771702866512, code=themeColor, value=null, createTime=1792982707658, updateTime=1792982707658, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428509671665695, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771702866512, code=themeStyle, value=.style-1 .main-menu ul>li { margin-right: 18px; } @media (max-width: 1442px) { .style-1 .main-menu ul>li a { font-size: 16px; padding: 10px 0; } }, createTime=1792982707660, updateTime=1792982707660, creator=18614031015, updator=18614031015)])], journalTitle=中国医药工业杂志, weixinUrl=null, journalUrl=http://www.cjph.com.cn/, iacademicId=null, status=1, seqNo=null, journalTitleEn=Chinese Journal of Pharmaceuticals, journalPhotoCn=etiWDuwx2KO274LHw88KJA==, journalPhotoEn=ip9NF4dK57AmNrCiZ6hmdw==, journalFirstLetter=Z, journalRecommend=null, journalNew=null, journalCollection=null, jcrJf=null, cjcrJf=null, jcrJfStr=null, cjcrJfStr=null, submissionFirstDecision=null, sciSubjectClassification=null, casSubjectClassification=null, citeScore=null, totalCitationFrequency=null, icpCode=null, psCode=null, advertisingLicenseCode=null, copyrightInformation=null, country=null, option=, provinceCode=null, provinceName=null, collectFlag=false, interPubPlatform=, interPubPlatformUrl=null), detailUrlCn=https://castjournals.cast.org.cn/joweb/zgyygy/CN/10.16522/j.cnki.cjph.2022.04.005, detailUrlEn=https://castjournals.cast.org.cn/joweb/zgyygy/EN/10.16522/j.cnki.cjph.2022.04.005, pdfUrlCn=https://castjournals.cast.org.cn/joweb/zgyygy/CN/PDF/10.16522/j.cnki.cjph.2022.04.005, pdfUrlEn=https://castjournals.cast.org.cn/joweb/zgyygy/EN/PDF/10.16522/j.cnki.cjph.2022.04.005, aliStartDate=0, aliEndDate=0, collectionFlag=false, citedCount=null, citedUrl=null, previewStatus=0, delFlag=0, hasFullText=0, orderTime=1649520000000, fullTextJson=null, articleText=null, reference=null)
收藏切换
小分子周期蛋白依赖性激酶4/6抑制剂药物及其专利研究
葛凡 1 , 孙建 2 , 黄璐 3, 4, *
中国医药工业杂志 | 综述 2022,53(4): 464-473
收起
收藏切换
中国医药工业杂志 |综述 2022 , 53 (4) : 464 -473
小分子周期蛋白依赖性激酶4/6抑制剂药物及其专利研究
全屏
[Author(id=1327673211837329586, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327673209094254753, orderNo=0, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1327673211946381492, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327673209094254753, authorId=1327673211837329586, language=EN, stringName=Fan GE, firstName=Fan, middleName=null, lastName=GE, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, address=1.FIWIS Intellectual Property Law Firm, Beijing 100032, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1327673212009296053, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327673209094254753, authorId=1327673211837329586, language=CN, stringName=葛凡, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, address=1.北京孚睿湾知识产权代理事务所,北京 100032, bio={"content":"

葛凡(1980—),男,博士,专利代理师,诉讼代理人,从事医药知识产权工作。

"}, bioImg=null, bioContent=

葛凡(1980—),男,博士,专利代理师,诉讼代理人,从事医药知识产权工作。

, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1327673211464036516, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327673209094254753, xref=1., ext=[AuthorCompanyExt(id=1327673211472425125, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327673209094254753, companyId=1327673211464036516, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.FIWIS Intellectual Property Law Firm, Beijing 100032), AuthorCompanyExt(id=1327673211480813734, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327673209094254753, companyId=1327673211464036516, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.北京孚睿湾知识产权代理事务所,北京 100032)])]), Author(id=1327673212076404919, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327673209094254753, orderNo=1, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1327673212156096697, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327673209094254753, authorId=1327673212076404919, language=EN, stringName=Jian SUN, firstName=Jian, middleName=null, lastName=SUN, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=2, address=2.Kanazawa Institute of Technology, Tokyo, Japan 105-0002, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1327673212290314426, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327673209094254753, authorId=1327673212076404919, language=CN, stringName=孙建, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=2, address=2.金泽工业大学,日本 东京都 105-0002, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1327673211556311207, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327673209094254753, xref=2., ext=[AuthorCompanyExt(id=1327673211564699816, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327673209094254753, companyId=1327673211556311207, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.Kanazawa Institute of Technology, Tokyo, Japan 105-0002), AuthorCompanyExt(id=1327673211568894121, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327673209094254753, companyId=1327673211556311207, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.金泽工业大学,日本 东京都 105-0002)])]), Author(id=1327673212403560636, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327673209094254753, orderNo=2, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=47153437@qq.com, emailSecond=null, emailThird=null, correspondingAuthor=1, authorType=1, ext={EN=AuthorExt(id=1327673212525195455, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327673209094254753, authorId=1327673212403560636, language=EN, stringName=Lu HUANG, firstName=Lu, middleName=null, lastName=HUANG, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=3, 4, *, address=3.School of Chemical Engineering and Pharmacy, Wuhan Institute of Technology, Wuhan 430205
4.School of Pharmacutical Sciences, Wuhan University, Wuhan 430071, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1327673212617470144, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327673209094254753, authorId=1327673212403560636, language=CN, stringName=黄璐, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=3, 4, *, address=3.武汉工程大学化工与制药学院,湖北 武汉 430205
4.武汉大学药学院,湖北 武汉 430071, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1327673211627614378, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327673209094254753, xref=3., ext=[AuthorCompanyExt(id=1327673211656974507, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327673209094254753, companyId=1327673211627614378, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=3.School of Chemical Engineering and Pharmacy, Wuhan Institute of Technology, Wuhan 430205), AuthorCompanyExt(id=1327673211673751724, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327673209094254753, companyId=1327673211627614378, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=3.武汉工程大学化工与制药学院,湖北 武汉 430205)]), AuthorCompany(id=1327673211753443502, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327673209094254753, xref=4., ext=[AuthorCompanyExt(id=1327673211766026415, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327673209094254753, companyId=1327673211753443502, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=4.School of Pharmacutical Sciences, Wuhan University, Wuhan 430071), AuthorCompanyExt(id=1327673211774415024, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327673209094254753, companyId=1327673211753443502, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=4.武汉大学药学院,湖北 武汉 430071)])])]
葛凡1, 孙建2, 黄璐3, 4, *
作者信息
  • 1.北京孚睿湾知识产权代理事务所,北京 100032
  • 2.金泽工业大学,日本 东京都 105-0002
  • 3.武汉工程大学化工与制药学院,湖北 武汉 430205
  • 4.武汉大学药学院,湖北 武汉 430071
通讯作者:
黄璐(1982—),男,高级工程师,从事新药开发与医药知识产权研究。E-mail:
作者简介:

葛凡(1980—),男,博士,专利代理师,诉讼代理人,从事医药知识产权工作。

Small Molecule Cyclin-dependent Kinase 4/6 Inhibitor Drugs and Their Patent Research
Fan GE1, Jian SUN2, Lu HUANG3, 4, *
Affiliations
  • 1.FIWIS Intellectual Property Law Firm, Beijing 100032
  • 2.Kanazawa Institute of Technology, Tokyo, Japan 105-0002
  • 3.School of Chemical Engineering and Pharmacy, Wuhan Institute of Technology, Wuhan 430205
  • 4.School of Pharmacutical Sciences, Wuhan University, Wuhan 430071
出版时间: 2022-04-10 doi: 10.16522/j.cnki.cjph.2022.04.005
文章导航
收藏切换

本研究重点对国内外已上市的5个小分子周期蛋白依赖性激酶4/6(CDK4/6)抑制剂药物及其专利信息进行解读,详细分析和研究了各药物在不同技术主题如化合物、晶型、盐型、制备工艺、药物制剂、药物组合物和(或)联合给药、药物新用途、衍生物等方面的专利情况,以期为我国医药企业进行CDK4/6抑制剂的创新药或仿制药产品立项与开发,以及进行新的专利挖掘、专利保护与布局时,提供有效的专利信息和文献依据。

CDK4/6抑制剂  /  哌柏西利  /  利柏西利  /  阿贝西利  /  曲拉西利  /  达尔西利  /  专利研究

In this study, five small-molecule cyclin-dependent kinase 4/6(CDK4/6) inhibitors, marketed at home and abroad, are analyzed and researched in detail, so does their patent information. To provide practical patent information and references for Chinese pharmaceutical companies to establish and develop projects of CDK4/6 inhibitors for innovative or generic drugs, as well as new patent mining, patent protection and layout, this study mainly focuses on the patents of product, crystalline form, salt form, process, formulation, drug combination, new use and development derivatives.

CDK4/6 inhibitor  /  palbociclib  /  ribociclib  /  abemaciclib  /  trilaciclib  /  dalpiciclib  /  patent research
葛凡, 孙建, 黄璐. 小分子周期蛋白依赖性激酶4/6抑制剂药物及其专利研究. 中国医药工业杂志, 2022 , 53 (4) : 464 -473 . DOI: 10.16522/j.cnki.cjph.2022.04.005
Fan GE, Jian SUN, Lu HUANG. Small Molecule Cyclin-dependent Kinase 4/6 Inhibitor Drugs and Their Patent Research[J]. Chinese Journal of Pharmaceuticals, 2022 , 53 (4) : 464 -473 . DOI: 10.16522/j.cnki.cjph.2022.04.005
  • 国家社会科学基金项目(18BFX168)
参考文献 引证文献
排序方式:
[1]
TOOGOOD P L, HARVEY P J, REPINE J T, et al.Discovery of a potent and selective inhibitor of cyclin-dependent kinase 4/6 [J].J Med Chem, 2005, 48(7): 2388-2406.
[2]
VANDERWEL S N, HARVEY P J, MCNAMARA D J, et al.Pyrido[2,3-d]pyrimidin-7-ones as specific inhibitors of cyclin-dependent kinase 4 [J].J Med Chem, 2005, 48(7):2371-2387.
[3]
PARDEE A B.G1 events and regulation of cell proliferation[J].Science, 1989, 246(4930): 603-608.
[4]
FINN R S, DERING J, CONKLIN D, et al.PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro [J].Breast Cancer Res,2009, 11(5): R77.
[5]
VANARSDALE T, BOSHOFF C, ARNDT K T, et al.Molecular pathways: targeting the cyclin D-CDK4/6 axis for cancer treatment [J].Clin Cancer Res, 2015, 21(13): 2905-2910.
[6]
ASGHAR U, WITKIEWICZ A K, TURNER N C, et al.The history and future of targeting cyclin-dependent kinases in cancer therapy [J].Nat Rev Drug Discov, 2015, 14(2):130-146.
[7]
KLEIN M E, KOVATCHEVA M, DAVIS L E, et al.CDK4/6 inhibitors: the mechanism of action may not be as simple as once thought [J].Cancer Cell, 2018, 34(1):9-20.
[8]
Clarivate Analytics公司.Cortellis数据库[EB/OL].[2021-11-23].https://www.cortellis.com/intelligence.
[9]
DHILLON S.Palbociclib: first global approval [J].Drugs,2015, 75(5): 543-551.
[10]
LU J.Palbociclib: a first-in-class CDK4/CDK6 inhibitor for the treatment of hormone-receptor positive advanced breast cancer [J].J Hematol Oncol, 2015, 8(1): 98.
[11]
U.S.FDA.Drugs@FDA: FDA-approved drugs-Ibrance(palbociclib) NDA #207103 [EB/OL].[2021-08-12].https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=207103.
[12]
U.S.FDA.Palbociclib(Ibrance)[EB/OL].[2021-08-12].https://www.fda.gov/drugs/resources-information-approved-drugs/palbociclib-ibrance.
[13]
U.S.FDA.Drugs@FDA: FDA-approved drugs-Ibrance(palbociclib) NDA #212436 [EB/OL].[2021-08-12].https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=212436.
[14]
U.S.FDA.Ribociclib (Kisqali)[EB/OL].[2021-08-12].https://www.fda.gov/drugs/resources-information-approved-drugs/ribociclib-kisqali.
[15]
BRAAL C L, JONGBLOED E M, WILTING S M, et al.Inhibiting CDK4/6 in breast cancer with palbociclib, ribociclib, and abemaciclib: similarities and differences [J].Drugs, 2021, 81(3): 317-331.
[16]
KNUDSEN E S, WITKIEWICZ A K.Defining the transcriptional and biological response to CDK4/6 inhibition in relation to ER+/HER2- breast cancer [J].Oncotarget,2016, 7(43): 69111-69123.
[17]
U.S.FDA.FDA approves abemaciclib for HR-positive, HER2-negative breast cancer [EB/OL].[2021-08-12].https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-abemaciclib-hr-positive-her2-negative-breast-cancer.
[18]
SLEDGE G W Jr, TOI M, NEVEN P, et al.MONARCH 2: abemaciclib in combination with fulvestrant in women with HR+/HER2 advanced breast cancer who had progressed while receiving endocrine therapy [J].J Clin Oncol, 2017,35(25): 2875-2884.
[19]
GOETZ M P, TOI M, CAMPONE M, et al.MONARCH 3: abemaciclib as initial therapy for advanced breast cancer[J].J Clin Oncol, 2017, 35(32): 3638-3646.
[20]
U.S.FDA.FDA approves abemaciclib as initial therapy for HR-positive, HER2-negative metastatic breast cancer[EB/OL].[2021-08-12].https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-abemaciclib-initial-therapy-hr-positive-her2-negative-metastatic-breast-cancer.
[21]
李瑞鹏,夏广新,赵建宏,等.阿贝西利的合成研究进展[J].中国医药工业杂志,2021,52(9):1142-1153.
[22]
PARYLO S, VENNEPUREDDY A, DHAR V, et al.Role of cyclin-dependent kinase 4/6 inhibitors in the current and future eras of cancer treatment [J].J Oncol Pharm Pract,2019, 25(1): 110-129.
[23]
U.S.FDA.FDA approves drug to reduce bone marrow suppression caused by chemotherapy [EB/OL].[2021-08-12].https://www.fda.gov/news-events/press-announcements/fda-approves-drug-reduce-bone-marrow-suppression-caused-chemotherapy.
[24]
先声药业官网.先声药业和G1 Therapeutics宣布签署有关Trilaciclib产品在大中华地区的独家许可协议[EB/OL].[2021-08-12].https://www.simcere.com/news/detail.aspx?mtt=98.
[25]
U.S.FDA.Drugs@FDA: FDA-Approved Drugs, labels for NDA 214200 [EB/OL].[2021-08-12].https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214200s000lbl.pdf.
[26]
XU B, ZHANG Q, ZHANG P, et al.Dalpiciclib versus placebo plus fulvestrant in HR+/HER2- advanced breast cancer that relapsed or progressed on previous endocrine therapy (DAWNA-1): amulticenter, randomized, phase 3 study [J].J Clin Oncol, 2021, 39(15_suppl): 1002.
[27]
黄璐,王亚楠,陈进,等.新丝裂原激活蛋白激酶激酶1/2抑制剂:司美替尼[J].中国新药与临床杂志,2021,40(8):562-568.
[28]
黄璐,古双喜,洪怡.选择性转染重排酪氨酸激酶抑制剂概述及其专利研究[J].中国医药工业杂志,2021,52(10):1291-1296.
[29]
黄璐,余浩,张长春,等.药品研发过程中的知识产权制度及运用[J].中国新药杂志,2019,28(1):10-16.
2022年第53卷第4期
65
14
0
引用本文
BibTeX
文章信息
doi: 10.16522/j.cnki.cjph.2022.04.005
  • 接收时间:2021-09-17
  • 首发时间:2026-11-12
  • 出版时间:2022-04-10
补充材料
相关文章
文章信息
作者
出版历史
  • 收稿日期:2021-09-17
基金
国家社会科学基金项目(18BFX168)
作者信息
    1.北京孚睿湾知识产权代理事务所,北京 100032
    2.金泽工业大学,日本 东京都 105-0002
    3.武汉工程大学化工与制药学院,湖北 武汉 430205
    4.武汉大学药学院,湖北 武汉 430071

通讯作者:

黄璐(1982—),男,高级工程师,从事新药开发与医药知识产权研究。E-mail:
参考文献
分享链接
https://castjournals.cast.org.cn/joweb/zgyygy/CN/10.16522/j.cnki.cjph.2022.04.005
分享至
全文二维码

扫描看全文

引用本文
BibTeX
本文的引用情况
2种不同金属材料的力学参数
科
Family
属数
Number of
genus
种数
Number of
species
占总种数比例
Percentage of
total species (%)
属
Genus
种数
Number of
species
占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏